Notably, 9 out of 12 (75%) PRL-3-expressing tumours also expressed higher ratios of phosphorylated 4E-BP1/total 4E-BP1 than their matched PRL-3-negative normal tissue samples (asterisks, Fig. 1a). This evidence concerns the gene PTP4A3 and neoplasm.